What is the recommended S‑1 chemotherapy regimen, including body‑surface‑area‑adjusted dosing, schedule, combination options, monitoring, and dose adjustments, for an adult patient with metastatic colorectal carcinoma and adequate performance status?

S-1 Chemotherapy Regimen in Metastatic Colorectal Carcinoma

S-1 is not a standard first-line or second-line treatment option for metastatic colorectal cancer according to established ESMO guidelines, which recommend fluoropyrimidine-based regimens using 5-FU or capecitabine in combination with oxaliplatin or irinotecan, plus targeted biologics. However, S-1 has demonstrated activity in Asian populations and may be considered in specific clinical contexts, particularly in Asian patients or when standard fluoropyrimidines are not tolerated.

Standard Fluoropyrimidine-Based Regimens (Guideline-Recommended)

The established first-line treatment for metastatic colorectal cancer consists of:

• FOLFOX or CAPOX regimens (fluoropyrimidine plus oxaliplatin) provide higher response rates, longer progression-free survival, and better overall survival than fluoropyrimidine monotherapy 1, 2.
• FOLFIRI regimens (5-FU/leucovorin/irinotecan) have similar activity to FOLFOX but different toxicity profiles, with more alopecia and diarrhea for irinotecan versus polyneuropathy for oxaliplatin 2.
• Capecitabine 2000 mg/m²/day on days 1-14 every 3 weeks combined with oxaliplatin 130 mg/m² on day 1 (CAPOX) is an established alternative to infused 5-FU regimens 2, 3.

S-1 Regimens in Asian Populations

In Asian populations, particularly Japanese patients, S-1-based regimens have been incorporated into treatment algorithms:

S-1 Plus Oxaliplatin (SOX)

• S-1 40 mg/m² twice daily on days 1-14 combined with oxaliplatin 130 mg/m² on day 1, every 3 weeks 4.
• This regimen demonstrated a 54% response rate with median progression-free survival of 8.5 months and overall survival of 27.2 months in a phase II study 4.
• SOX plus bevacizumab is recognized as a combination option in Pan-Asian adapted ESMO guidelines 5.

S-1 Plus Irinotecan

• S-1 80 mg/m²/day on days 3-7,10-14, and 17-21 with irinotecan 60 mg/m² on days 1,8, and 15 of a 28-day cycle showed a 48.9% response rate with median progression-free survival of 8.1 months 6.
• An alternative schedule uses S-1 on days 1-14 with irinotecan 150 mg/m² on day 1, every 3 weeks, achieving a 62.5% response rate 7.
• S-1 plus irinotecan plus bevacizumab is recognized in Pan-Asian guidelines as non-inferior to FOLFOX/CAPOX plus bevacizumab in first-line treatment 5.

Body Surface Area-Adjusted Dosing for S-1

S-1 dosing is adjusted based on body surface area (BSA):

• BSA <1.25 m²: 40 mg twice daily
• BSA 1.25-1.5 m²: 50 mg twice daily
• BSA >1.5 m²: 60 mg twice daily 8, 7

Combination with Targeted Agents

When S-1 regimens are used, they should be combined with targeted biologics:

• Bevacizumab (7.5 mg/kg on day 1) can be added to S-1-based doublets, improving response rates to 67% and progression-free survival to approximately 12 months 9, 7.
• The combination of SOX plus bevacizumab is specifically endorsed in Pan-Asian guidelines for first-line treatment 5.

Monitoring and Dose Adjustments

Key toxicities requiring monitoring include:

• Gastrointestinal toxicity: Diarrhea (6-10% grade 3/4) and stomatitis are the most common dose-limiting toxicities with S-1 regimens 8, 6.
• Hematologic toxicity: Neutropenia occurs in 8-26% of patients at grade 3/4 9, 6, 7.
• Hand-foot syndrome: Less common with S-1 compared to capecitabine 7.

Dose modifications:

• For grade 3 gastrointestinal toxicity, reduce S-1 dose by one level (e.g., from 60 mg to 50 mg twice daily) 8.
• Treatment interruptions should be considered for cumulative toxicity while maintaining disease control 2, 3.

Clinical Context and Caveats

Critical limitations:

• S-1 is not mentioned in standard ESMO guidelines for Western populations 1, 2, 3, where capecitabine and 5-FU remain the fluoropyrimidine standards.
• The evidence for S-1 comes primarily from Asian populations, particularly Japanese patients, where it has demonstrated comparable efficacy to standard regimens 5.
• The recommended treatment schedule is 2 weeks of S-1 followed by a 2-week rest when combined with leucovorin, based on dose-limiting toxicity profiles 8.

When S-1 might be considered:

• In Asian patients where regional guidelines support its use 5, 10.
• When standard fluoropyrimidines (5-FU or capecitabine) are not tolerated or available.
• In clinical trial settings exploring novel combinations 8, 9, 6.

Standard of care remains: FOLFOX, CAPOX, or FOLFIRI combined with bevacizumab or EGFR antibodies (in RAS wild-type tumors) for first-line treatment of metastatic colorectal cancer in most populations 3.